A new Congressional report concluded that Emergent BioSolutions (NYSE:EBS) attempted to hide evidence related to quality problems before informing the FDA that 15 million COVID-19 vaccines were contaminated.
Prepared for Rep. Carolyn Maloney (D-NY) and James E. Clyburn (D-SC), the report from the House and the Select Subcommittee on the Coronavirus Crisis scrutinizes the quality controls in Emergent’s Bayview plant in Baltimore.
In particular, the House report concluded that Emergent workers removed quality-assurance “hold” tags from Johnson & Johnson vaccine batches before an FDA inspection.
The Bayview plant had served as the only U.S. manufacturing site for the J&J COVID-19 vaccine.
The report relies on internal communications from Emergent executives to determine whether the company attempted to elude government oversight.
It also noted that the FDA, J&J and AstraZeneca employees identified problems at the …